LPCN LIPOCINE INC Other Situations 8-K Filing 2023 - FDA Meeting and Study Announcement Lipocine announces successful meeting with FDA and plan to initiate study for LPCN 1154 targeting postpartum depression.Get access to all SEC 8-K filings of the LIPOCINE INC